AbbVie Drug Pipeline

AbbVie is a large pharmaceutical company with a substantial clinical development portfolio, encompassing 971 registered trials since 2008, including 184 currently active studies. These active trials span a range of phases, with 64 in Phase 1, 59 in Phase 2, 74 in Phase 3, and 5 in Phase 4. AbbVie's research activity extends across 17 therapeutic areas, with a significant concentration in oncology, which accounts for approximately 60% of active programs (110 trials). Within oncology, the leading indications are solid tumor (advanced) with 17 active trials (including 2 in Phase 3), multiple myeloma with 16 active trials (including 4 in Phase 3), non-small cell lung cancer (NSCLC) with 12 active trials (including 4 in Phase 3), ovarian cancer with 9 active trials (including 1 in Phase 3), and colorectal cancer with 8 active trials (including 2 in Phase 3). Beyond oncology, AbbVie maintains a presence in immunology (29 active trials), central nervous system (CNS) disorders (16 active trials), ophthalmology (12 active trials), dermatology (5 active trials), and cardiovascular disease (2 active trials). The relatively high number of Phase 3 trials suggests a potential for near-term pipeline catalysts.